New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical Therapeutics

• Publication date

  2003-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0149-2918(03)80195-9PMID 12946541
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

  2003cited by this paper
• Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones.

  2003cited by this paper
• Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

  2002cited by this paper
• Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO‐HOPE

  2002cited by this paper
• Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus

  2002cited by this paper
• The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

  2002cited by this paper
• Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.

  2002cited by this paper
• Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

  2002cited by this paper
• Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes

  2002cited by this paper
• Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

  2002cited by this paper
• Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.

  2002cited by this paper
• Long-term efficacy of triple oral therapy for type 2 diabetes mellitus.

  2002cited by this paper
• Diabetes Therapeutics News

  2002cited by this paper
• Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

  2002cited by this paper
• Clinical evidence of thiazolidinedione‐induced improvement of pancreatic β‐cell function in patients with type 2 diabetes mellitus

  2002cited by this paper
• A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.

  2002cited by this paper
• Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.

  2002cited by this paper
• Lipid management in diabetic patients: lessons from prevention trials.

  2002cited by this paper
• The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management - 2002 Update

  2002cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

  2001cited by this paper
• Oral therapies for diabetic hyperglycemia.

  2001cited by this paper
• C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.

  2001cited by this paper
• Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.

  2001cited by this paper
• Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.

  2001cited by this paper
• The Effect of a Thiazolidinedione Drug, Troglitazone, on Glycemia in Patients with Type 2 Diabetes Mellitus Poorly Controlled with Sulfonylurea and Metformin: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

  2001cited by this paper
• Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.

  2001cited by this paper
• Hepatotoxicity with Thiazolidinediones

  2001cited by this paper
• The continuing epidemics of obesity and diabetes in the United States.

  2001cited by this paper
• The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study.

  2001cited by this paper
• Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

  2001cited by this paper
• A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

  2001cited by this paper
• Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

  2001cited by this paper
• Nonhypoglycemic Effects of Thiazolidinediones

  2001cited by this paper
• Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study

  2001cited by this paper
• Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells.

  2000cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.

  2000cited by this paper
• Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review.

  2000cited by this paper
• Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.

  2000cited by this paper
• Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

  2000cited by this paper
• Long-Term Prevention of Bone Loss

  2000cited by this paper
• Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

  2000cited by this paper
• Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

  2000cited by this paper
• Conclusions from the VA-HIT study.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Insulin resistance and cardiovascular disease.

  2000cited by this paper
• Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.

  2000cited by this paper
• Expression and Function of PPARγ in Rat and Human Vascular Smooth Muscle Cells

  2000cited by this paper
• The New England Journal

  2000cited by this paper
• Rosiglitazone

  1999cited by this paper
• C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.

  1999cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

  1999cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study.

  1999cited by this paper
• Pharmacologic Therapy for Type 2 Diabetes Mellitus

  1999cited by this paper
• Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.

  1999cited by this paper
• Dyslipidemia of central obesity and insulin resistance.

  1999cited by this paper
• Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes.

  1998cited by this paper
• Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes.

  1998cited by this paper
• Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

  1998cited by this paper
• Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994

  1998cited by this paper
• Lactic acidosis in patients with diabetes treated with metformin.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Consensus Development Conference on Insulin Resistance: 5–6 November 1997

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.

  1998cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study.

  1997cited by this paper
• Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study.

  1997cited by this paper
• Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

  1997cited by this paper
• Troglitazone Improves Defects in Insulin Action , Insulin Secretion , Ovarian Steroidogenesis , and Fibrinolysis in Women with Polycystic Ovary Syndrome *

  1997cited by this paper
• Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project.

  1997cited by this paper
• Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

  1997cited by this paper
• Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.

  1997cited by this paper
• Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes

  1996cited by this paper
• Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.

  1996cited by this paper
• Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study.

  1995cited by this paper
• Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.

  1995cited by this paper
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

  1995cited by this paper
• Clinical implications of insulin resistance syndromes.

  1995cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles.

  1993cited by this paper
• Impaired Insulin-Mediated Skeletal Muscle Blood Flow in Patients With NIDDM

  1992cited by this paper
• Pathogenesis of NIDDM: A Balanced Overview

  1992cited by this paper
• Insulin and Cardiovascular Disease: Paris Prospective Study

  1991cited by this paper
• Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations

  1979cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• A novel berberine derivative targeting adipocyte differentiation to alleviate TNF-α-induced inflammatory effects and insulin resistance in OP9 cells.

  2023cites this paper
• WJCPR11 reverses the TNF-α-induced inhibition of adipocyte differentiation and glucose uptake.

  2021cites this paper
• Antidiabetic effects of Brucea javanica seeds in type 2 diabetic rats

  2017cites this paper
• Thiazolidinediones abrogate cervical cancer growth

  2017cites this paper
• Efficacy of Some Combination Regimens of Oral Hypoglycaemic Agents in Type 2 Diabetes Mellitus Patients

  2015cites this paper
• The effect of plant-derived oleanolic acid on selected markers of lipid metabolism and insulin signalling pathway in streptozotocin-induced diabetic rats.

  2014influential citation
• AN OVERVIEW OF DIABETES MELLITUS AND SUGAR LOWERING PLANTS

  2014cites this paper
• Interaction of rosiglitazone and pioglitazone with organic cation transporters

  2013cites this paper
• Bioinformatic studies of the disposition pathways and targets of synthetic drugs and herbal medicines

  2011cites this paper
• Stability-indicating validated HPLC method for simultaneous determination of oral antidiabetic drugs from thiazolidinedione and sulfonylurea groups in combined dosage forms.

  2010cites this paper
• Type 2 diabetes: fueling the surge of cardiovascular disease in women.

  2008cites this paper
• Pharmacokinetic Interactions with Thiazolidinediones

  2007cites this paper
• Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk.

  2007cites this paper
• Diabetes: Treatment Options Report

  2006cites this paper
• Diabetes, Obesity, and Metabolic Syndrome

  2006cites this paper
• Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.

  2005cites this paper
• Vers une trithérapie orale dans le traitement pharmacologique du diabète de type 2

  2005cites this paper
• Drug Interactions of Clinical Importance with Antihyperglycaemic Agents

  2005cites this paper
• Aspectos prácticos en el tratamiento del paciente diabético tipo 2

  2004cites this paper
• Combined Thiazolidinedione-Insulin Therapy

  2004cites this paper
• Studies on the potential utilization of glucose-dependent insulinotropic polypeptide (GIP) in type 1 and type 2 diabetes

  2004influential citation
• The Calcium Channel Antagonist Benidipine Reduces Plasma and Cardiac Endothelin-1 Levels in Type II Diabetic Rat Model

  2004cites this paper
• Current literature in diabetes.

  2004cites this paper